Skip to main content
SpringerLink
Log in

A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

The potent serotonin receptor (5-HT3) antagonists are new highly selective agents for the prevention and control of chemotherapy-induced nausea and vomiting that have been shown to be comparable to or more effective than traditional metoclopramide regimens. This study was designed to compare the antiemetic efficacy of dolasetron and metoclopramide in chemotherapy-naive and non-naive cancer patients receiving high-dose cisplatin-containing chemotherapy. This multicentre, double-blind, randomized trial compared the efficacy and safety of single i.v. doses of dolasetron mesilate salt (1.2 or 1.8 mg/kg) and metoclopramide (7 mg/kg) in 226 patients for the prevention of acute emesis and nausea associated with the administration of high-dose (≥80 mg/m2) cisplatin. Efficacy and safety were evaluated for 24 h. Complete responses were achieved by 57%, 48%, and 35% of patients given dolasetron mesilate 1.8 mg/kg (P=0.0009 vs metoclopramide), dolasetron mesilate 1.2 mg/kg (P=0.0058 vs metoclopramide), and metoclopramide, respectively. Overall, dolasetron was significantly more effective than metoclopramide for time to first emetic episode, nausea, patient satisfaction, and investigator global assessment of efficacy. Males, chemotherapy-naive patients, and alcoholics had higher response rates. Dolasetron was well tolerated, with mild-to-moderate headache most commonly reported. Twelve percent of patients receiving metoclopramide reported extrapyramidal symptoms compared with 0% of patients receiving dolasetron. In conclusion, dolasetron mesilate was effective for the prevention of CINV with high-dose cisplatin. Single i.v. doses of dolasetron mesilate were more effective than 7 mg/kg metoclopramide in preventing nausea and vomiting induced by highly emetogenic cisplatin-containing chemotherapy. In addition, 1.8 mg/kg dolasetron mesilate consistently produced the highest response rates and appears to be the most effective dose for further clinical development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aapro MS (1991) 5-HT3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis. Drugs 42:551–568

    PubMed  Google Scholar 

  2. Allen JC, Gralla R, Reilly L, et al (1985) Metoclopramide: dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy. J Clin Oncol 3:1136–1141

    PubMed  Google Scholar 

  3. Audhuy B, Cappelaere P, Claverie N, et al (1995) Double-blind comparison of the antiemetic efficacy of two single iv doses of dolasetron and one iv dose of granisetron after cisplatin (≥80 mg/m2) chemotherapy (abstract). Support Care Cancer 5:338

    Google Scholar 

  4. Bateman DN, Rawlins MD, Simpson JM (1985) Extrapyramidal reactions with metoclopramide. BMJ 291:930–932

    PubMed  Google Scholar 

  5. Bigaud M, Elands J, Kastner PR, et al (1995) Pharmacology of the human metabolites of dolasetron, an antiemetic 5-HT3 receptor antagonist. Drug Dev Res 34:289–296

    Google Scholar 

  6. Boeijinga PH, Galvan M, Baron BM, et al (1992) Characterization of the novel 5-HT3 antagonists MDL 73147EF (dolasetron mesylate) and MDL 74156 in NG108-15 neuroblastoma × glioma cells. Eur J Pharmacol 219:9–13

    PubMed  Google Scholar 

  7. Boxenbaum H, Gillespie T, Heck K, et al (1992) Human dolasetron pharmacokinetics. I. Disposition following single-dose intravenous administration to normal male subjects. Biopharm Drug Dispos 13:693–701

    PubMed  Google Scholar 

  8. Conroy T, Cappelaere P, Fabbro M, et al (1994) Acute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT3 antagonist, in cancer patients treated with cisplatin. Am J Clin Oncol 17:97–102

    PubMed  Google Scholar 

  9. Cooper S, Georgiou V (1992) The impact of cytotoxic chemotherapy -perspectives from patients, specialists and nurses. Eur J Cancer 28A [Suppl 1]:S36-S38

    PubMed  Google Scholar 

  10. Cunningham D, Soukop M, Gilchrist NL, et al (1985) Randomised trial of intravenous high-dose metoclopramide and intramuscular chlorpromazine in controling nausea and vomiting induced by cytotoxic drugs. BMJ 290:604–605

    PubMed  Google Scholar 

  11. D'Aquisto R, Tyson LB, Gralla RJ, et al (1986) The influence of chronic high alcohol intake on chemotherapyinduced nausea and vomiting (abstract). Proc Am Soc Clin Oncol 5:257

    Google Scholar 

  12. De Mulder PHM, Seynaeve C, Vermorken JB, et al (1990) Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 113:834–840

    PubMed  Google Scholar 

  13. Galvan M, Gittos MW, Fatmi M (1993) Dolasetron mesylate. Drugs Future 18:506–509

    Google Scholar 

  14. Gordon CJ, Pazdur R, Ziccarelli A, et al (1989) Metoclopramide versus metoclopramide and lorazepam: superiority of combined therapy in the control of cisplatin-induced emesis. Cancer 63:578–582

    PubMed  Google Scholar 

  15. Gralla RJ (1993) Current issues in the management of nausea and vomiting. Ann Oncol 4 [Suppl 3]:S3-S7

    Google Scholar 

  16. Gralla RJ, Itri LM, Pisko SE, et al (1981) Antiemetic efficacy of highdose metoclopramide: randomised trials with placebo and prochlorperazine in patients with chemotherapy induced nausea and vomiting. N Engl J Med 305:905–909

    PubMed  Google Scholar 

  17. Gralla RJ, Tyson LB, Kris MG, et al (1987) The management of chemotherapy-induced nausea and vomiting. Med Clin North Am 72:289–300

    Google Scholar 

  18. Grunberg SM, Hesketh PJ (1993) Control of chemotherapy-induced emesis. N Engl J Med 329:1790–1796

    PubMed  Google Scholar 

  19. Grunberg SM, Stevenson LL, Russell CA, et al (1989) Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatininduced nausea and vomiting. J Clin Oncol 7:1137–1141

    PubMed  Google Scholar 

  20. Hainsworth J, Harvey W, Pendergrass K, et al (1991) A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol 9:721–728

    PubMed  Google Scholar 

  21. Harman GS, Omura GA, Ryan K, Hainsworth JD, Cramer MB, Hahne WF (1996) A randomized, doubleblind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis. Cancer Chemother Pharmacol 38:323–328

    PubMed  Google Scholar 

  22. Hesketh PJ (1991) Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst 83:613–620

    PubMed  Google Scholar 

  23. Hesketh PJ, Gandara DR, Hesketh AM, et al (1996) Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide. Support Care Cancer 4:141–146

    PubMed  Google Scholar 

  24. Kirchner V, Aapro M, Alberto P, et al (1993) Early clinical trial of MDL 73,147 EF: a new 5HT3-receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann Oncol 4:481–484

    PubMed  Google Scholar 

  25. Kris MG, Gralla RJ, Tyson LB, et al (1985) Improved control of cisplatininduced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients. Cancer 55:527–534

    PubMed  Google Scholar 

  26. Kris MG, Gralla RJ, Clark RJ, et al (1987) Antiemetic control and prevention of side effects of anticancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. Cancer 60:2816–2822

    PubMed  Google Scholar 

  27. Kris MG, Grunberg SM, Gralla RJ, et al (1994) Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol 12:1045–1049

    PubMed  Google Scholar 

  28. Lazlo J (1983) Nausea and vomiting as major complications of cancer chemotherapy. Drugs 25 [Suppl 1]:1–7

    Google Scholar 

  29. Markham A, Sorkin EM (1993) Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. Drugs 45:931–952

    PubMed  Google Scholar 

  30. Marty M, Pouillart P, Scholl S, et al (1990) Comparison of the 5-hydroxytryptamine-3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322:816–821

    PubMed  Google Scholar 

  31. Merrouche Y, Catimel G, Rebattu P, et al (1994) A phase I antiemetic study of MDL 73,147EF, a novel 5-hydroxytryptamine antagonist in cancer patients receiving emetogenic chemotherapy. Ann Oncol 5:549–551

    PubMed  Google Scholar 

  32. Miller RC, Galvan M, Gittos MW, et al (1993) Pharmacological properties of dolasetron, a potent and selective antagonist at 5-HT3 receptors. Drug Dev Res 28:87–93

    Google Scholar 

  33. Navari RM, Kaplan HG, Gralla RJ, et al (1994) Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 12:2204–2210

    PubMed  Google Scholar 

  34. Peace KM (1990) Statistical issues in drug research and development. Dekker, New York

    Google Scholar 

  35. Riviere A (1994) Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. Br J Cancer 69:967–971

    PubMed  Google Scholar 

  36. Roila F, Tonato M, Basurto C, et al (1987) Anti-emetic activity of high-dose metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized doubleblind trial of the Italian Oncology Group for Clinical Research. J Oncol 5:141–149

    Google Scholar 

  37. Sledge GW Jr, Einhorn L, Nagy C, et al (1992) Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer 70:2524–2528

    PubMed  Google Scholar 

  38. Sullivan JR, Leyden MJ, Bell R (1983) Decreased cisplatin induced nausea and vomiting with chronic alcohol ingestion. N Engl J Med 309:796–797

    Google Scholar 

  39. Tortorice PV, O'Connell MB (1990) Management of chemotherapy-induced nausea and vomiting. Pharmacotherapy 10:129–145

    PubMed  Google Scholar 

  40. Warrington PS, Allan SG, Cornbleet MA, et al (1986) Optimising antiemetics in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high-dose metoclopramide in emesis induced by cisplatin. BMJ 293:1334–1337

    PubMed  Google Scholar 

  41. Yielding A, Bertoli L, Eisenberg P, et al (1996) Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy. Am J Clin Oncol (in press)

Download references

Author information

Authors and Affiliations

  1. Service d'Oncologie Médicale, Centre H. Becquerel, F-76038, Rue d'Amiens, Rouen, France

    B. Chevallier & P. Bastit

  2. Centre Oscar Lambre, Lille, France

    P. Cappelaere

  3. University Hospital Dijksigt, Rotterdam, The Netherlands

    T. Splinter

  4. Centre Val d'Aurelle, Montpellier, France

    M. Fabbro

  5. Hôpital Saint-Louis, Toulon, France

    J. L. Wendling

  6. Hôpital Coste Boyere, La Garde, Toulon, France

    L. Cals

  7. Centre Léon Bérard, Lyon, France

    G. Catimel

  8. Institut J. Paoli-Calmettes, Marseille, France

    M. Giovannini

  9. Groupe Hospitalier de la Pitie-Salpetriere, Paris, France

    D. Khayat

  10. Hoechst Marion Roussel, Inc., Strasbourg, France

    N. Claverie

Authors
  1. B. Chevallier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Cappelaere
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Splinter
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Fabbro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. L. Wendling
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L. Cals
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Catimel
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Giovannini
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D. Khayat
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. P. Bastit
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. N. Claverie
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chevallier, B., Cappelaere, P., Splinter, T. et al. A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy. Support Care Cancer 5, 22–30 (1997). https://doi.org/10.1007/BF01681958

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01681958

Key words

Search

Navigation